vs
COASTAL FINANCIAL CORP（CCB）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
COASTAL FINANCIAL CORP的季度营收约是再鼎医药的1.1倍（$138.0M vs $127.1M），再鼎医药同比增速更快（17.1% vs -5.8%），COASTAL FINANCIAL CORP自由现金流更多（$246.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -3.6%）
富达国民金融是美国财富500强企业，面向房地产与按揭行业提供产权保险及交割服务。2019年，其产权及房地产业务相关年营收约为84.69亿美元，是行业内具有领先地位的金融服务提供商。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CCB vs ZLAB — 直观对比
营收规模更大
CCB
是对方的1.1倍
$127.1M
营收增速更快
ZLAB
高出22.9%
-5.8%
自由现金流更多
CCB
多$272.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-3.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $138.0M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 12.4% | -54.6% |
| 净利率 | — | — |
| 营收同比 | -5.8% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.84 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCBZLAB
| Q4 25 | $138.0M | $127.1M | ||
| Q3 25 | $144.7M | $115.4M | ||
| Q2 25 | $119.4M | $109.1M | ||
| Q1 25 | $139.5M | $105.7M | ||
| Q4 24 | $146.5M | $108.5M | ||
| Q3 24 | $151.1M | $101.8M | ||
| Q2 24 | $135.3M | $100.1M | ||
| Q1 24 | $148.4M | $87.1M |
净利润CCBZLAB
| Q4 25 | — | — | ||
| Q3 25 | $13.6M | $-36.0M | ||
| Q2 25 | $11.0M | $-40.7M | ||
| Q1 25 | $9.7M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.5M | $-41.7M | ||
| Q2 24 | $11.6M | $-80.3M | ||
| Q1 24 | $6.8M | $-53.5M |
毛利率CCBZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CCBZLAB
| Q4 25 | 12.4% | -54.6% | ||
| Q3 25 | 12.4% | -42.3% | ||
| Q2 25 | 12.0% | -50.3% | ||
| Q1 25 | 8.4% | -53.3% | ||
| Q4 24 | 11.7% | -62.6% | ||
| Q3 24 | 10.8% | -66.6% | ||
| Q2 24 | 11.1% | -76.0% | ||
| Q1 24 | 5.9% | -80.7% |
净利率CCBZLAB
| Q4 25 | — | — | ||
| Q3 25 | 9.4% | -31.2% | ||
| Q2 25 | 9.2% | -37.3% | ||
| Q1 25 | 7.0% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 8.9% | -40.9% | ||
| Q2 24 | 8.6% | -80.2% | ||
| Q1 24 | 4.6% | -61.4% |
每股收益（稀释后）CCBZLAB
| Q4 25 | $0.84 | $-0.05 | ||
| Q3 25 | $0.88 | $-0.03 | ||
| Q2 25 | $0.71 | $-0.04 | ||
| Q1 25 | $0.63 | $-0.04 | ||
| Q4 24 | $0.95 | $-0.09 | ||
| Q3 24 | $0.97 | $-0.04 | ||
| Q2 24 | $0.84 | $-0.08 | ||
| Q1 24 | $0.50 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $491.0M | $715.5M |
| 总资产 | $4.7B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCBZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
股东权益CCBZLAB
| Q4 25 | $491.0M | $715.5M | ||
| Q3 25 | $475.3M | $759.9M | ||
| Q2 25 | $461.7M | $791.7M | ||
| Q1 25 | $449.9M | $810.8M | ||
| Q4 24 | $438.7M | $840.9M | ||
| Q3 24 | $331.9M | $667.7M | ||
| Q2 24 | $316.7M | $704.2M | ||
| Q1 24 | $303.7M | $762.2M |
总资产CCBZLAB
| Q4 25 | $4.7B | $1.2B | ||
| Q3 25 | $4.6B | $1.2B | ||
| Q2 25 | $4.5B | $1.2B | ||
| Q1 25 | $4.3B | $1.2B | ||
| Q4 24 | $4.1B | $1.2B | ||
| Q3 24 | $4.1B | $985.3M | ||
| Q2 24 | $4.0B | $987.4M | ||
| Q1 24 | $3.9B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $254.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $246.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 178.3% | -21.0% |
| 资本支出强度资本支出/营收 | 6.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $436.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CCBZLAB
| Q4 25 | $254.6M | $-26.0M | ||
| Q3 25 | $59.0M | $-32.0M | ||
| Q2 25 | $66.0M | $-31.0M | ||
| Q1 25 | $71.7M | $-61.7M | ||
| Q4 24 | $259.8M | $-55.8M | ||
| Q3 24 | $62.6M | $-26.8M | ||
| Q2 24 | $72.1M | $-42.2M | ||
| Q1 24 | $56.8M | $-90.1M |
自由现金流CCBZLAB
| Q4 25 | $246.1M | $-26.7M | ||
| Q3 25 | $57.4M | $-35.0M | ||
| Q2 25 | $64.0M | $-33.9M | ||
| Q1 25 | $68.9M | $-63.2M | ||
| Q4 24 | $249.9M | $-58.4M | ||
| Q3 24 | $60.2M | $-28.2M | ||
| Q2 24 | $69.5M | $-42.9M | ||
| Q1 24 | $55.0M | $-91.1M |
自由现金流率CCBZLAB
| Q4 25 | 178.3% | -21.0% | ||
| Q3 25 | 39.7% | -30.4% | ||
| Q2 25 | 53.6% | -31.1% | ||
| Q1 25 | 49.4% | -59.9% | ||
| Q4 24 | 170.6% | -53.8% | ||
| Q3 24 | 39.8% | -27.7% | ||
| Q2 24 | 51.3% | -42.9% | ||
| Q1 24 | 37.1% | -104.5% |
资本支出强度CCBZLAB
| Q4 25 | 6.1% | 0.5% | ||
| Q3 25 | 1.2% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 2.0% | 1.5% | ||
| Q4 24 | 6.8% | 2.4% | ||
| Q3 24 | 1.6% | 1.3% | ||
| Q2 24 | 1.9% | 0.7% | ||
| Q1 24 | 1.2% | 1.1% |
现金转化率CCBZLAB
| Q4 25 | — | — | ||
| Q3 25 | 4.34× | — | ||
| Q2 25 | 5.99× | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.65× | — | ||
| Q2 24 | 6.22× | — | ||
| Q1 24 | 8.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCB
| Other | $74.7M | 54% |
| Baa S Credit Enhancements | $47.3M | 34% |
| Baa S Program Income | $8.4M | 6% |
| Transaction Fees | $4.9M | 4% |
| Servicing And Other Baa S Fees | $1.6M | 1% |
| Baa S Fraud Enhancements | $1.1M | 1% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
